Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

Blueprint Medicines won FDA approval for Ayvakit (avapritinib), the first treatment for gastrointestinal stromal tumors (GISTs) that targets platelet-derived growth factor alpha (PDGFR) exon 18.